Jeff Jonas

Chief Executive Officer, Sage Therapeutics

Jeff joined Sage as CEO in 2013 and has more than 20 years of experience in the pharmaceutical and healthcare industries. In 2019, the FDA approved Sage’s brexanolone injection, the first new drug specifically indicated for women with postpartum depression.

Part of the Power List 2019

Breakthroughs at the bench, novel technologies and groundbreaking policies and regulation have helped the pharma industry grow from strength to strength. After months of collating reader nominations and judging overseen by a panel of industry experts, we proudly present The Medicine Maker 2019 Power List, featuring 100 of the industry’s pioneers across four categories: Industry Influencers, Business Captains, Masters of the Bench, and Champions of Change.

Go to The Power List 2019